This discrepancy may be partly attributable to results indicating that the albuminuria-reducing effect of SGLT2 inhibitors is more remarkably attenuated in patients without diabetes compared to those with diabetes [19,20]. This evidence concerns the gene SLC5A2 and diabetes mellitus.